Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 3,086 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma
Interventions
Mivavotinib, Paclitaxel, Pharmacokinetic Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Cancer
Interventions
AGEN2373, Botensilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Coral Gables, Florida + 9 more
Conditions
Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
Interventions
NKTR-262, bempegaldesleukin, nivolumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
Interventions
PQ203
Drug
Lead sponsor
ProteinQure Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • West Valley City, Utah
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors
Interventions
RMC-5127, daraxonrasib, cetuximab
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions
PRT3789, Docetaxel
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more
Conditions
Advanced Solid Tumor (Phase 1)
Interventions
CUG279
Biological
Lead sponsor
Cugene Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
Interventions
PT-112 Injection
Drug
Lead sponsor
Promontory Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more
Conditions
Adult Solid Neoplasm, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Conditions
Solid Tumor
Interventions
Capecitabine, 5-Fluorouracil (5-FU), Irinotecan, Cisplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
Interventions
Axatilimab, Durvalumab
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Baltimore, Maryland • Portland, Oregon + 1 more
Conditions
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Interventions
Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam, Digoxin, Rosuvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more
Conditions
Advanced Solid Tumor, Malignant Solid Tumor
Interventions
Ifinatamab deruxtecan (I-DXd)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 6 more
Conditions
Cancer, Neoplasms
Interventions
GSK2820151
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Detroit, Michigan • Nashville, Tennessee
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAS0612
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Solid Tumors, Adult
Interventions
HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer, RCC, Clear Cell Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Endometrial Cancer
Interventions
ADU-1805, Pembrolizumab
Drug
Lead sponsor
Sairopa B.V.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Detroit, Michigan • St Louis, Missouri • Charlotte, North Carolina + 5 more
Conditions
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
Interventions
TRK-950
Biological
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Conditions
Advanced Solid Tumors
Interventions
VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-214662, trastuzumab, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Neoplasms, Solid Tumors
Interventions
TdCyd
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Cabozantinib, Pamiparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Tumor, Adult
Interventions
AXN-2510
Biological
Lead sponsor
Axion Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Huntersville, North Carolina • Dallas, Texas • Houston, Texas + 2 more